Who is sponsoring NCT02961595?

NCT02961595 is sponsored by Tampere University.

What condition does NCT02961595 study?

NCT02961595 studies Enterovirus Infection, Type 1 Diabetes, Prediabetic State.

What drugs are being tested in NCT02961595?

Interventions: Oral Polio Vaccine (OPV).

What is the status of NCT02961595?

NCT02961595 is currently COMPLETED.

Last reviewed 2024-07-18 · How we verify

Live Enterovirus Vaccine and Type 1 Diabetes

NCT02961595 Phase 1 COMPLETED Results posted

Enterovirus infections may either increase or decrease the risk of type 1 diabetes depending on the age of infection and the type of enterovirus in question. This study evaluated whether early serial exposures to three replication-competent enterovirus strains (live poliovirus vaccine, OPV) can influence the immunity to other enteroviruses and the possible initiation of autoantibodies e.g. islet autoimmunity in young genetically predisposed children.

Details

Lead sponsor	Tampere University
Phase	Phase 1
Status	COMPLETED
Enrolment	315
Start date	1999-10
Completion	2016-11

Conditions

Enterovirus Infection
Type 1 Diabetes
Prediabetic State

Interventions

Oral Polio Vaccine (OPV)

Primary outcomes

Number of Participants With the Appearance of Type 1 Diabetes Associated Auto-antibodies in Serum — Through study completion, an average of 11 years
Appearance of multiple type 1 diabetes associated auto-antibodies (2-4 of the measured four auto-antibodies ICA, IAA, GADA, IA-2A)